GIST-IMPACT
20.6.2024 08:01:35 CEST | Business Wire | Press release
Today GIST Impact, the leading provider of impact data and analytics, announced an investment from UBS Next, the leading universal Swiss bank’s venture and innovation unit.
GIST Impact delivers actionable impact intelligence to companies and investors, helping them easily measure their environmental and social impacts. The firm’s data and software are founded on a science-based, location-specific and standards-aligned approach, drawing on over 16 years of experience measuring and valuing impact. Its clients include some of the world’s largest banks, sovereign wealth funds, and technology firms.
The provision of better impact data is critical in developing greater transparency for investors to help them manage their portfolios. New regulations and standards have also set a higher bar for measuring impact across value chains - whether through assessing impact materiality as part of the Corporate Sustainability Reporting Directive (CSRD) or evaluating natural capital impact as part of the Taskforce on Nature-related Financial Disclosures (TNFD).
The investment from UBS Next will support the further expansion of GIST Impact’s product integrations with partners and development of proprietary impact data and software solutions, including preparations for CSRD and TNFD requirements where clients require most support.
Andre Hoffmann, Co-Founder of GIST Impact, said, “This partnership with UBS marks a pivotal moment for GIST Impact as we set new standards for how companies and investors can integrate environmental and social considerations into their core business strategies. Our collaboration is more than an investment; it's a shared commitment to foster a more sustainable future where financial success is inextricably linked to positive impact on the planet and society. We are thrilled to join forces with UBS to drive this change forward, ensuring that our clients are not just prepared for the future but are actively shaping it."
“We believe that actionable impact intelligence and data will help investors manage their portfolios in a targeted manner and match opportunities and environmental and social impact. This is a pre-requisite to create long-term sustainable outcomes,” said Sergio Ermotti, Group CEO of UBS.
“We’re proud to partner with UBS to accelerate this next stage in our growth. Our world-leading impact data and intelligence algorithms empower investors to manage their portfolios towards better social and environmental outcomes and impacts,” said Pavan Sukhdev, Co-Founder and CEO of GIST Impact. “Furthermore, our impact valuation platforms help companies evaluate their impacts, dependencies, risks and opportunities, helping create long-term sustainable value.”
About GIST Impact
GIST Impact is a market-leading impact data and analytics provider, measuring, quantifying and valuing corporate impacts on society and the environment for over 16 years. With a team of 120+ data scientists, engineers, ecologists and economists, GIST Impact delivers location-specific impact data covering 14,500+ companies. Since 2021, the firm has automated its systems to provide investment portfolio impacts, and its clients include investors representing over $8 trillion in assets under management as well as leading global corporations. GIST Impact also partners with some of the largest consulting firms, business networks, and fintech platforms to enable impact measurement and reporting across global markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619424763/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom